Company*
(Country; Symbol)

University/
Non-Profit@

Type Of
Agreement

Product Area

Details (Date)


AaiPharma
Inc.
(AAII)

University of North Carolina

Technology transfer agreement

To facilitate the transfer of scientific discoveries by university researchers into medicines

Financial details were not disclosed (9/26)

Actinium Pharmaceuticals
Inc.*

Memorial Sloan-Kettering Cancer Center

Agreement

For alpha particle immunotherapy, which targets cancer cells

Actinium will provide supporting patent position for use of the short half-life alpha particle-emitting radioisotopes (10/2)

Affymetrix
Inc.
(AFFX)

Whitehead Institute/MIT Center for Genome Research

Research collaboration

To use Affymetrix GeneChip technology to conduct cancer clinical studies

The collaboration is designed to standardize experimental procedures and further validate numerous studies demonstrating the power of expression data for cancer classification (9/16)

Agencourt Bioscience
Corp.*

Emory University School of Medicine

Agreement

To provide its SeeSNP Discovery and Agen-TYPE Genotyping services for targeted identification and study of single nucleotide polymorphism markers with potential relevance to thrombosis risk

Researchers expect the technology to help them identify and study polymorphisms in several essential genes of the coagulation system (9/30)

Alfacell
Corp.
(OTC
BB:ACEL)

National Cancer Institute

Research collaboration

To evaluate Alfacell's Onconase as a radiation enhancer

Further details were not disclosed (9/19)

Ambion
Inc.*

University of Massachusetts

Worldwide, exclusive research market license agreement

For a patent application focused on vector technology for expressing small interfering RNA

Financial terms were not disclosed (11/11)

Anacor Pharma-
ceuticals Inc.*

Defense Advanced Research Projects Agency

Contract

To develop therapeutics to counter the effects of a biological attack

The contract is worth $21.6M (10/29)

AngioGenex
Inc.*

Albert Einstein College of Medicine at Yeshiva University

Licensing agreement

For patented inventions focusing on Id2 research to treat and diagnose certain cancers

Further details were not disclosed (9/5)

Applied
Biosystems

Group
(NYSE:
ABI)

Institute for
Systems Biology

Collaboration

To develop technologies and applications in proteomics

The institute plans to use Applied's 4700 Proteomics Analyzer with TOF/TOF Optics and the ICAT reagent technology (8/27)

ARC Pharma-
ceuticals
Inc.*

McGill University (Canada)

Research agreement

To support the development of antisense oligonucleotide therapeutics for cancer, including melanoma

ARC has the right to an exclusive license for each technology developed through one collaboration (8/12)

ARC Pharma-
ceuticals
Inc.*

University of British Columbia (Canada)

Exclusive licensing agreement

For the development and commercial sale of a class of anti-inflammatory compounds

ARC will provide the university with milestone and royalty payments in addition to equity in the company (11/1)

Ariad Pharma-
ceuticals
Inc.
(ARIA)

WiCell Research Institute Inc.

Agreement

To allow scientists at academic and other non-profit centers to use Ariad's cell-signaling regulation technology to control the function and fate of WiCell's human embryonic stem cells

Ariad also gains an option to obtain licenses to available WiCell technology and patents to develop discoveries made in that area (9/17)

Axonyx Inc.
(AXYX)

University of Melbourne (Australia)

Research agreement

For a process targeted at identifying early biochemical events associated with beta-amyloid toxicity

The agreement is for three years (9/24)

Axonyx Inc.
(AXYX)

U.S. Army Medical Research Institute of Chemical Defense

Extended agreement

To continue to study Axonyx's acetylcholin esterase- and butyryl- cholinesterase-inhibiting compounds for testing against chemical war- fare agents

The agreement is extended for two years (10/15)

Biolog Inc.*

The Institute for Genomic Research

Licensing agreement

To characterize phenotypes of bacterial strains, including Salmonella typhimurium, Streptococcus pneumoniae, Staphylococcus aureus, Synechococcus sp. and Escherichia coli

Both parties will share certain intellectual property rights from new discoveries identified using the PM technology, and they will exclusively license any discoveries that have potential commercial applications (10/1)

BioVex Ltd.*
(UK)

U.S. Public Health Service

Worldwide patent license agreement

For exclusive use of human melanoma antigens MART-1 and gp100 in therapeutic cancer vaccines based on herpes virus vectors

The melanoma antigens will be used by BioVex in its therapeutic vaccine, ImmunoVEX tri-melan (9/24)

Cangene
Corp.
(Canada;
TSE:CNJ)

Centers for Disease Control and Prevention

Contract

To develop and supply a vaccinia immune globulin for use in treating and preventing reactions that may be brought on by the administration of the smallpox vaccine

The five-year contract calls for Cangene to supply a maximum of 100,000 doses (8/12)

Cangene
Corp.
(Canada;
TSE:CNJ)

Centers for Disease Control and Prevention

Contract agreement

To develop a clinical- grade hyperimmune globulin to be used as an adjunct to antibiotic therapy in critically ill patients with anthrax infection

The globulin would be used for preclinical studies and human compassionate use and safety testing (9/24)

Cangene
Corp.
(Canada;
TSE:CNJ)

Canadian government

Research and technology agreements

To improve Canada's readiness for chemical, biological, radiological or nuclear incidents

The first project will use Can- gene's knowledge in developing therapeutic antibodies for the Ebola and Marburg viruses, while the second project will test Cangene's Leucotropin to treat white blood cell damage resulting from radiation exposure; the project is being funded as part of a C$170M (US$108M) five-year program (9/17)

Celera
Diagnostics

(joint venture between Applied Biosystems Group, NYSE:ABI; and Celera Genomics Group, NYSE: CRA)

University of California at San Francisco

Research agreement

For breast cancer studies with the goal of identifying genetic markers associated with the disease

The research activities will be funded in part by the UC Discovery Grant from the Industry- University Cooperative Research Program (11/7)

Cellestis
Ltd.*

Statens Serum Institut (Denmark)

Exclusive rights agreement

To use proteins specific to tuberculosis developed by Statens Serum Institut

The proteins will be used in a tuberculosis test developed by Cellestis (10/9**)

Cel-Sci Corp.
(AMEX:CVM)

Cincinnati Children's Hospital Medical Center

Agreement

To evaluate Cel-Sci's compound, CEL-1000, for protection against herpes in a guinea pig vaginal model

CEL-1000 has shown high levels of protection against herpes simplex, malaria and cancer in animal testing (9/26)

Cel-Sci Corp.
(AMEX:CVM)

Naval Medical Research Center

Cooperative research and development agreement

To jointly evaluate a newly discovered small peptide, derG, for protective and therapeutic efficacy for malaria

The peptide induced responses that were 100% effective against malaria in a mouse model (9/18)

Cerus Corp.
(CERS)

Army Medical Research acquisition activity division of the Department of Defense

Cooperative agreement

For continued development of technologies to improve the safety and availability of blood to use for blood transfusions

The agreement is worth $6.5M for Cerus to conduct research on inactivation of infectious blood-borne agents (9/26)

Cerylid
Biosciences
Ltd.*
(Australia)

Peter MacCallum Cancer Institute

Collaboration

To investigate anti-cancer drug leads

Cerylid will screen its library of natural products to identify inhibitors of protein kinases (10/29)

Corgenix
Medical
Corp.
(OTC
BB:CONX)

Okayama University Graduate School of Medicine and Dentistry (Japan)

Technology license agreement

To develop a technology related to antiphospholipid antibodies and atherosclerosis

Corgenix gains an exclusive, worldwide license (except in Japan) to use the technology, based on the interaction of oxidized LDL with B2GPl and a method to determine human oxidized lipoproteins (10/2)

Crucell NV
(the Netherlands;
CRXL)

Johns Hopkins
University

Agreement

To conduct research on therapeutic human monoclonal antibodies for treatment of langerhans cell histiocytosis

Crucell identified a panel of fully human monoclonal antibodies that bind to LCH cells, which will be validated by Johns Hopkins in its LCH models (8/16)

Crucell NV
(the Netherlands;
CRXL)

Vaccine Research Center of the National Institute of Allergy and Infectious Diseases

Cooperative research and development agreement

For the development of vaccines for Marburg and Lassa infections

Crucell entered an agreement with NIAID in May 2002 to develop an Ebola vaccine (8/7); it signed a manufacturing contract in October for Ebola, Lassa and Marburg vaccines (10/14)

Cyclis Pharma-
ceuticals
Inc.*

Beth Israel Deaconess Medical Center and the Dana-Farber Cancer Institute

Licensing agreement

For exclusive, world- wide rights to technology from Beth Israel and Dana-Farber

The technology expands Cyclis' Activated Checkpoint Therapy platform (10/9)

Debiopharm
SA*

(Switzerland)

University Henri Poincare (France)

Licensing agreement

For technology based on the formulation of microparticles prepared with blends of biodegradable and polycationic polymers to examine the feasibility of developing oral delivery of macromolecules

A feasibility study first will focus on low-molecular-weight heparin to identify the best parameters in terms of oral bioavailability and prolonged release for the active ingredient (10/24)

De Novo Pharmaceuticals
Ltd.*
(UK)

Cancer Research Ventures Ltd. (UK) and the Northern Institute for Cancer Research at the University of Newcastle (UK)

Collaboration

To discover small- molecule inhibitors of the p53-MDM2 interaction

De Novo will provide software to develop small-molecule inhibitors based on seed molecules provided by the institute (8/19)

DiaDexus
Inc.*

Emory University

Collaboration

To further evaluate the biological role of Nox-1, a cancer target and enzyme known to convert oxygen into reactive oxygen

DiaDexus will have the exclusive right to develop and commercialize therapeutic and diagnostic products targeting or otherwise based on Nox-1 (9/9)

DiaDexus
Inc.*

University of Michigan

Research agreement

To use proteomic technologies for the comprehensive analysis of cell surface membrane proteins to identify new drug targets and biomarkers useful for treating and diagnosing cancer

DiaDexus will provide research funding in exchange for the exclusive option to license intellectual property rights for resulting therapeutic and diagnostic products; the university will receive milestone and royalty payments based on products that result (9/4)

DOR
BioPharma
Inc.
(AMEX:
DOR)

University of Texas Medical Branch

Option agreement

To license patent applications covering the use of oral luminally active anti-inflammatory drugs, such as orBec, to treat irritable bowel syndrome

UTMB will test orBec in post-colitis animal models of functional bowel pain (9/26)

EluSys
Therapeutics
Inc.*

University of Texas at Austin

Collaboration

To test a complete anthrax antitoxin in animals for the first time

The collaboration is scheduled for one year, but can be extended (10/1)

EluSys
Therapeutics
Inc.*

U.S. Army Medical Research and Material Command

Agreement

For the development of Heteropolymer technology against anthrax toxin

The government is funding $2.8M for the project (9/8)

Emergent
Technologies
nc.*

University of Oklahoma Health Sciences Center

Licensing agreement

For a recombinant chondroitin technology

ETI has formed a new company, Choncept LLC, to commercialize the technology of Paul DeAngelis, an associate professor at UOHSC (10/28)

Epigenomics
AG*
(Germany)

Mayo Clinic

Agreement

To identify and validate a panel of DNA methylation-based markers to be applied in a test to improve the early detection of colorectal cancer

The Mayo Clinic will provide Epigenomics with samples of clinical materials from patient populations (11/5)

Epimmune
Inc.
(EPMN)

National Institute of Allergy and Infectious Diseases

Contract

To fund research aimed at developing a malaria vaccine

The contract is worth $3.5M for over five years (10/3)

Ferring
Pharma-
ceuticals
Inc.
(unit of Ferring Holdings SA; Switzerland)

Beth Israel
Deaconess
Medical Center

Agreement

To discover and develop drugs for osteoporosis

The agreement will focus on the role of the parathyroid hormone and its receptor in bone metabolism (10/31)

First Genetic
Trust Inc.*

International
Genomics
Consortium

Alliance

For First Genetic to be the exclusive provider of genetic banking systems and cancer genomes services for the consortium's initiative to sequence multiple

The consortium plans to establish a uniform system for obtaining, processing and characterizing human tumor samples and then build a publicly available database of gene expression in human cancer (9/5)

Ganeden
Biotech
Inc.*

Department of Defense

Agreement

For a topical strategy for the prevention and treatment of fungal infections in U.S. Marine Corps personnel

Preliminary studies will be conducted to determine the safety and efficacy of Ganeden's topical antifungal lotion (8/9)

Genencor International
Inc.
(GCOR)

University of Leicester (UK)

Collaboration

To identify metabolic and genetic diversity as a source of new and valuable products

Genencor and the university will work with three other organizations to discover microbes, genes and enzymes from unique and remote Chinese environments in Inner Mongolia and Tibet (10/8)

IGEN International
Inc.
(IGEN)

U.S. Department of Agriculture

Expanded agreement

To provide government regulatory agencies and commercial food processors with rapid methods to more accurately detect pathogens in public food and water supplies

The parties will work on the development of Origen-based tests for pathogens such as Vibrio and Staphylococcus aureus, and toxins such as botulism and Shiga toxin (9/30)

Illumina Inc.
(ILMN)

University of Cambridge (UK)

Agreement

To provide single nucleotide polymorph- ism genotyping services on a sample collection provided by the university's Cambridge Institute for Medical Research

Illumina will design functional assays for the SNP loci provided by CIMR, and then use its Bead-Array technology to genotype specified SNPs in the set of about 3,000 samples (8/27)

Inhibitex
Inc.*

Biopharmaceutical Technology Center (Singapore)

Research collaboration

To jointly develop production cell lines and a cGMP manufacturing process for humanized monoclonal antibodies

The collaboration will merge certain technologies and know-how in an effort to more rapidly bring products to the market (9/18)

Inspire
Pharmaceuticals

Inc.
(ISPH)

Cystic Fibrosis Foundation Therapeutics Inc.

Collaboration

To fund a Phase II study for INS37217 Respiratory to treat cystic fibrosis

Cystic Fibrosis Foundation Therapeutics will provide the majority of funding of external costs for the group study in exchange for post-commercialization milestone payments to be made following FDA approval (10/4)

International Therapeutics
Inc.

City of Hope National Medical Center

Research collaboration

To evaluate and characterize small interfering RNA molecules against HIV

International Therapeutics and the medical center will co-own the intellectual property resulting from the collaboration (10/17)

Kaleidos
Pharma Inc.*

Division of AIDS at the National Institute of Allergy and Infectious Diseases

Research collaboration

To conduct a non- human primate study to evaluate the potential of Kaleidos' transforming growth factor alpha com- pound to increase CD4 T-cell counts in rhesus monkeys infected with simian immunodeficiency virus

Further details were not disclosed (11/13)

Kaleidos
Pharma Inc.*

National Institute of Neurological Disorders and Stroke

Materials cooperative research and development agreement

To conduct primate studies to evaluate the potential of TGF-alpha in the treatment of Parkinson's disease

NIH researchers will obtain KPI's compound, transforming growth factor-alpha, to conduct the primate studies (9/24)

KS Biomedex
Holdings plc*
(UK)

Oxford University
(UK)

Licensing agreement

For protein trimers to be used as the basis of a drug discovery program

KSB believes the trimers can be engineered so that one end binds tightly and specifically to cancer cells, while another will carry a radioactive isotope or other cytotoxic (10/2**)

Kosan Bio-
sciences Inc.
(KOSN)

National Cancer Institute

Cooperative research and development agreement

For the clinical development of 17-AAG and for the development of improved geldanamycin analogues

Kosan also received an exclusive license to the institute's portfolio covering these and related compounds (11/4)

Lexrite
Labs Inc.*

Stanford University and the University of California

Licensing agreement

For exclusive, world- wide rights to Lexrite's Pretargeting Technology

Further details were not disclosed (9/9)

Marshall
Edwards
Inc.
(subsidiary of
Novogen Ltd.;
Australia;
NVGN)

Yale University School of Medicine's department of obstetrics and gynecology

Services agreement

For research screening cancer drugs for their ability to kill ovarian cancer cells, and to switch off a mechanism that ovarian cancer cells depend on for survival

Yale researchers found that Marshall's cancer drug, phenoxodiol, has an effect against ovarian cancer cells (8/27)

Microscience
Ltd.*
(UK)

University System of Maryland

Licensing agreement

For access to the university system's Bactofection DNA vaccine technology that would make it possible to deliver DNA vaccines orally

Microscience will apply the rights acquired to the delivery of DNA from a live bacterial vector in all fields, except HIV antigens that have been retained by the university system (9/8)

Morphochem
AG*
(Germany)

Fox Chase Cancer Center

Research collaboration

To develop new treatment for cancer

Collaboration will focus on progressing new compounds in the area of Ras pathway modulators toward the clinic (10/16)

Nanospectra
Biosciences
Inc.*

University of Texas M.D. Anderson Cancer Center

Option agreement

For the right to license technology developed through its ongoing collaborations

M.D. Anderson received a minority equity interest in Nanospectra, which gained a right to license technology used in conjunction with its Nanoshell technology (9/25)

Nanosphere
Inc.*

U.S. Government Technical Support working group

Contract

To apply Nanosphere's biomolecular detection system to the detection of biological warfare agents in various media

Nanosphere will optimize its platform into a field-deployable detection system that will test samples from water sources (10/3)

Neurogenetics
Inc.*

University of California

Research agreement

To characterize a target linked to Alzheimer's disease

Further details were not disclosed (9/9)

New Drug
Associates
Inc.*

University of Alabama

Licensing agreement

For technology that targets a lipoprotein remnant

The technology comprises a series of small peptides that mimic the function of Apolipoprotein E (9/10)

Novuspharma
SpA
(Italy;
Nuovo Mercato:
NOV)

National Cancer Institute

Cooperative research and development agreement

To discover and develop small- molecule inhibitors of hypoxia inducible factor 1-alpha

Novuspharma will provide technical expertise and reagents for the development of biochemical assays targeting HIF-1 alpha (9/24)

NuGEN
Technologies
Inc.*

Genome Institute of Singapore

Research collaboration

To work together to advance NuGEN's amplification and labeling technology for gene expression profiling on GIS's custom-made oligonucleotide microarrays

NuGEN's SPIA amplification for gene expression profiling from very small RNA samples will be used in the discovery research programs (10/15)

Optimer
Pharmaceuticals
Inc.*

Memorial Sloan- Kettering Cancer Center

Exclusive worldwide license

To a cancer vaccine already in clinical development

Optimer acquired the license and will oversee the commercialization of the Globo H vaccine (10/1)

Orchid
BioSciences
Inc.
(ORCH)

Office of the Chief Medical Examiner of New York City

Contract agreement

For Orchid to continue the process of identifying victims of the World Trade Center terrorist attacks

About half of the 3,000 victims could not be identified through regular DNA testing; Orchid will use its single nucleotide polymorphism analysis technology to analyze remaining DNA samples (8/29)

Oxford
GlycoSciences

plc
(UK; OGSI;
LSE:OGS)

FDA's Center for Drug Evaluation and Research

Cooperative research and development agreement

To identify serum protein biomarkers that could be useful in predicting and evaluating drug- induced toxicities

The FDA will begin a program to develop specific models of drug-induced histopathologic injury to the myocardium, vasculature and liver and will produce samples (9/19)

Oxigene
Inc.
(OXGN)

The Foundation Fighting Blindness Inc.

Research agreement

To advance vision-related research of Combrestatin A4 Prodrug

The agreement is conditioned upon certain regulatory and institutional review board approvals (10/31)

Paradigm
Genetics Inc.
(PDGM)

National Institute of Environmental Health Sciences

Five-year contract

To use gene expression profiling to measure the physiological effects of a toxicant, drug or pesticide on an organism, using equipment, software and arrays by Agilent Technologies Inc.

The contract is worth $23.8M (10/1)

Perlegen
Sciences
Inc.*

University of Michigan, the University of Southern California, the National Public Health Institute of Finland and the National Human Genome Research Institute

Collaborative research and development agreement

To study the genetic basis of Type II diabetes

Perlegen will use human genetic variations it discovered and its high-density oligonucleotide array-based SNP genotyping capacity to assist researchers from around the world in intensifying their search for genes involved in the disease (10/28)

PharmQuest
Corp.*

FDA's Center for Drug Evaluation and Research

Cooperative research and development agreement

To develop a toxicology and carcinogenicity data management system

PharmQuest will collaborate to develop the database for animal data equipped with electronic submissions and software tools to assist reviewers in the evaluation of data (9/25)

Phytomedics
Inc.*

Rutgers University

Research and licensing agreement

For work conducted at the Biotechnology Center for Agriculture and the Environment on Rutgers' Cook College campus

The five year, $4.3M agreement funds the work in exchange for the right to exclusively license resulting technologies and pro- ducts; Rutgers acquired about $1M in Phytomedics' stock (8/19)

Progen
Industries

Ltd.
(Australia;
PGLAF)

Australia's Commonwealth Science and Industrial Research Organization

Agreement

To research, develop and manufacture new drugs

Early stage drug research may be directed to Progen; Progen can tap into the organization's process optimization knowledge (8/19)

Progen
Industries

Ltd.
(Australia;
PGLAF)

Unisearch (commercialization company of the University of New South Wales)

Exclusive licensing agreement

To license and develop a newly patented cancer therapy

The candidate, PI-166, is in late- stage preclinical development and has shown anticancer activity in laboratory and animal studies (9/18)

Prometheus
Laboratories
Inc.*

National Public Health Institute

License agreement

For intellectual property related to two highly sensitive and specific DNA variations to a gene associated with adult-type hypolactasia

Agreement covers any and all applications of the technology and is exclusive worldwide with the exception of Finland, the Baltic States and Russia, where it is nonexclusive (10/10)

ProSanos
Corp.*

Windber Research Institute

Partnership

To apply ProSanos' knowledge in data integration and analysis to information derived from the institute's array of biological samples

The companies initially will focus on heart disease (9/25)

Psychiatric
Genomics
Inc.*

Harvard Brain Tissue Resource Center

Agreement

To provide tissue extracts from normal control schizophrenic and biopolar subjects

Psychiatric Genomics uses gene expression analysis of human tissues to develop small-molecule drugs to treat mental health disorders (8/20)

Psychiatric
Genomics
Inc.*

National Institute of Psychiatry and Neurology (Hungary)

Collaboration

To develop therapeutics to treat schizophrenia and bipolar disorder

Psychiatric Genomics will have exclusive access to brain tissue from individuals diagnosed with bipolar disorder, schizophrenia and other psychiatric disorders, from which the company will determine patterns of gene expression to further its gene and drug discovery programs (9/17)

Pyrosequencing
AB
(Sweden;
SSE:PYROA)

Harvard University

Exclusive license agreement

For access to nucleic acid technology that can be used in applications such as DNA sequencing

Pyrosequencing gains expanded rights to fluorescent nucleotide technology that can be used to analyze DNA in conjunction with Pyrosequencing's sequencing by synthesis technology or with other platforms (8/14)

Q3DM Inc.*

The Scripps Research Institute

Access agreement

For certain biosensor technology

Q3DM gains access to the technology and plans to improve early error discovery in the drug development process (10/14)

Regma Bio
Technologies
Ltd.
(UK; OTC BB:RBTL)

Naval Medical Research Center

Cooperative research and development agreement

To explore the potential biological assets and capabilities of Regma regarding the diagnostic and therapeutic treatment of anthrax

The agreement also will focus on discovering and developing capabilities that build on existing strengths of both parties (8/22)

Structural
GenomiX
Inc.*

National Institutes of Health

Agreement

To manage $18.1M over three years in a public-private venture focused on protein structure research

Structural GenomiX will share the funding with other New York Structural Genomics Research Consortium participants, including scientists at the Albert Einstein College of Medicine, the Brookhaven National Laboratory, Columbia University, The Rockefeller University and the Weill Medical College of Cornell University (11/14)

SurroMed
Inc.*

University of California at Davis

Agreement

To use SurroMed's technology in the search for biological markers of autism

SurroMed will analyze clinical samples from children with autism provided by the UC Davis M.I.N.D. Institute (11/4)

Symyx
Technologies
Inc.
(SMMX)

North Dakota State University

Purchase agreement

For four Symyx Discovery Tools modules

The school will use the units in the synthesis, analysis and evaluation of large numbers of polymers and coatings formulations (10/1)

The Institute
for
Systems
Biology

National Heart, Lung and Blood Institute

Contract

To develop technology in the proteomics field

The contract, worth $19.8M, is meant to establish the institute as one of 10 centers nationwide for the National Heart, Lung and Blood Institute's long-term proteomics initiative (10/9)

TransForm
Pharmaceuticals
Inc.*

Massachusetts Institute of Technology

License agreement

To strengthen and broaden TransForm's position in high-throughput pharmaceutical form and formulation

MIT provided TransForm with access to technology that will enable automated microscale dispensing of dry powder materials (10/7)

U.S.
Genomics*

Defense Advanced Research Projects Agency

Contract agreement

To examine the use of U.S. Genomics' direct linear DNA analysis technology to detect pathogens such as anthrax and smallpox

Contract is worth $449,500 (9/4)

VaxGen Inc.
(VXGN)

National Institute of Allergy and Infectious Diseases

Contracts

To spur development of a new anthrax vaccine

The contracts total $22.5M through fiscal year 2003 (10/3)

ViaCell
Inc.*

Massachusetts Institute of Technology

Licensing agreement

For dimerized fibroblast growth factor

The license includes rights to intellectual property covering dFGF and its use in treatment of all neurological disorders (8/14)

Vion Pharma-
ceuticals
Inc.
(VION)

National Cancer Institute

Agreement

For Triapine development

NCI's Cancer Therapy Evaluation Program will sponsor trials of Triapine to further explore its activity as a single agent or in combination with other agents in patients with cancer (11/5)

Virax Holdings
Ltd.
(Australia; ASX:VHL)

New York Blood Center

Development agreement

For treatments for hepatitis B virus infection

Virax will contribute its Co-X- Gene technology and viral vector knowledge to commercialize the blood center's HBV research; Virax will retain commercial rights to further develop the most promising leads (8/19)

Viventia
Biotech
Inc.
(Canada;
TSE:VBI)

The University of Texas M.D. Anderson Cancer Center

Option agreement

For two hybridoma cell lines

Viventia licensed the lines, in which the first hybridoma produces antibodies that target ovarian and endometrial malignancies and the other targets squamous cell carcinomas (10/4)

Viventia
Biotech
Inc.
(Canada;
TSE:VBI)

University of Zurich (Switzerland)

Exercised option agreement

For a single-chain immunotoxin to be developed as a lead candidate for Viventia's Armed Antibodies targeted therapeutics platform

Viventia initially will develop and assess the therapeutic, VB4- 845, as a treatment for head and neck cancer (10/1)

Vyrex Corp.
(VYRX)

National Institute of Neurological Disorders and Stroke

Cooperative research and development agreement

To use Panavir to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage

Further details were not disclosed (8/14)

Xeotron
Corp.*

Michigan State University

Research collaboration

To advance the study of microorganisms in the environment

Xeotron's microfluidic XeoChip platform will be used at MSU's Center for Microbial Ecology to understand and identify genetic alterations that enable microorganisms to be useful in bioremediation projects (10/16)


Notes:

This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes the date the item ran in BioWorld International.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange